nach oben

Pituitary

Erschienen in:

01.04.2015

Clinical and biochemical manifestations of Cushing’s

verfasst von: Georgia Ntali, Ashley Grossman, Niki Karavitaki

Erschienen in: Pituitary | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cushing’s syndrome is associated with a number of clinical manifestations and co-morbidities which may not resolve even after long-term remission leading to excessive mortality.

Materials and methods

This review summarizes the main manifestations of Cushing’s syndrome (active or in remission) with particular focus on data from recently published literature.

Conclusion

Obesity and metabolic alterations, hypertension and cardio/cerebrovascular complications, hypercoagulability/thromboembolism, neuropsychiatric, muscle/skeletal and immune consequences remain the most challenging. Cardiovascular consequences and immunosuppression determine the main causes of death in Cushing’s syndrome necessitating early intervention when possible.

Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N (2013) Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169:715–723CrossRefPubMed

Yaneva M, Kalinov K, Zacharieva S (2013) Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 169:621–627CrossRefPubMed

Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, Cooper MS, Johnson AP, Stewart PM (2012) Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 97:1194–1201CrossRefPubMed

Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642CrossRefPubMed

Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM, ERCUSYN Study Group (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165:383–392CrossRefPubMed

Geer EB, Shen W, Gallagher D, Punyanitya M, Looker HC, Post KD, Freda PU (2010) MRI assessment of lean and adipose tissue distribution in female patients with Cushing’s disease. Clin Endocrinol 73:469–475

Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M (2008) Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab 93:4969–4973CrossRefPubMed

Geer EB, Shen W, Strohmayer E, Post KD, Freda PU (2012) Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 97:1702–1711CrossRefPubMedCentralPubMed

Libè R, Morpurgo PS, Cappiello V, Maffini A, Bondioni S, Locatelli M, Zavanone M, Beck-Peccoz P, Spada A (2005) Ghrelin and adiponectin in patients with Cushing’s disease before and after successful transsphenoidal surgery. Clin Endocrinol 62:30–36CrossRef

10.

Veldman RG, Frölich M, Pincus SM, Veldhuis JD, Roelfsema F (2001) Hyperleptinemia in women with Cushing’s disease is driven by high-amplitude pulsatile, but orderly and eurhythmic, leptin secretion. Eur J Endocrinol 144:21–27CrossRefPubMed

11.

Krsek M, Silha JV, Jezková J, Hána V, Marek J, Weiss V, Stepán JJ, Murphy LJ (2004) Adipokine levels in Cushing’s syndrome; elevated resistin levels in female patients with Cushing’s syndrome. Clin Endocrinol 60:350–357CrossRef

12.

Setola E, Losa M, Lanzi R, Lucotti P, Monti LD, Castrignanò T, Galluccio E, Giovanelli M, Piatti P (2007) Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing’s disease from metabolic syndrome. Clin Endocrinol 66:586–592

13.

Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94:3365–3371CrossRefPubMed

14.

Valassi E, Biller BM, Klibanski A, Misra M (2012) Adipokines and cardiovascular risk in Cushing’s syndrome. Neuroendocrinology 95:187–206CrossRefPubMed

15.

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 61:768–777CrossRef

16.

Giordano R, Picu A, Marinazzo E, D’Angelo V, Berardelli R, Karamouzis I, Forno D, Zinnà D, Maccario M, Ghigo E, Arvat E (2011) Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol 75:354–360CrossRef

17.

Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after 5 years of successful cure. J Clin Endocrinol Metab 84:2664–2672PubMed

18.

Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M (2010) Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology 92(suppl. 1):86–90CrossRefPubMed

19.

Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, Cozzolino A, Colao A (2013) Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur J Endocrinol 170:311–319CrossRefPubMed

20.

Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab 98:1022–1030CrossRefPubMedCentralPubMed

21.

Mazziotti G, Gazzaruso C, Giustina A (2011) Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 22:499–506CrossRefPubMed

22.

Cicala MV, Mantero F (2010) Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(suppl. 1):44–49CrossRefPubMed

23.

Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS (2003) Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 149:549–553CrossRefPubMed

24.

Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 87:3662–3666PubMed

25.

Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 163:783–791CrossRefPubMed

26.

Van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA (2013) Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol 78:481–488CrossRef

27.

Dusek T, Kastelan D, Solak M, Basic Kinda S, Aganovic I, Korsic M (2008) Polycythemia as the first manifestation of Cushing’s disease. J Endocrinol Invest 31:940CrossRefPubMed

28.

Miljic P, Miljic D, Cain JW, Korbonits M, Popovic V (2012) Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 11:21–30PubMed

29.

Stuijver DJ, Van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, van den Berg G, Pereira AM, de Herder WW, Wagenmakers MA, Kerstens MN, Zelissen PM, Fliers E, Schaper N, Drent ML, Dekkers OM, Gerdes VE (2011) Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525–3532CrossRefPubMed

30.

Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller HR, Brandjes DP (2009) Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 94:2743–2750CrossRefPubMed

31.

Kastelan D, Dusek T, Kraljevic I, Aganovic I (2013) Hypercoagulable state in Cushing’s syndrome is reversible following remission. Clin Endocrinol 78:102–106CrossRef

32.

van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Lamberts SW, Hofland LJ, Feelders RA (2012) The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303–1310CrossRefPubMed

33.

Dekkers OM, Horváth-Puhó E, Jørgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM, Sørensen HT (2013) Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277–2284CrossRefPubMed

34.

Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, Korbonits M, Besser GM, Anastasakis A, Grossman AB (2011) Specific electrocardiographic features associated with Cushing’s disease. Clin Endocrinol 74:558–564CrossRef

35.

Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F, Pecori Giraldi F (2012) Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin Endocrinol 76:332–338CrossRef

36.

Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA (2010) Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur J Endocrinol 162:331–340CrossRefPubMed

37.

Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, Feelders RA, Bax JJ, Pereira AM (2012) Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur J Endocrinol 166:27–34CrossRefPubMed

38.

Hey TM, Dahl JS, Brix TH, Søndergaard EV (2013) Biventricular hypertrophy and heart failure as initial presentation of Cushing’s disease. BMJ Case Rep. doi:10.1136/bcr-2013-201307 PubMed

39.

Rotondi M, Dionisio R, Fonte R, Caporotondi A, Guazzotti G, Baccheschi J, Febo O, Castellano M, Chiovato L (2011) Dilated cardiomyopathy: a possibly underestimated presentation of Cushing’s disease. Clin Endocrinol 75:864–865CrossRef

40.

Chandran DS, Ali N, Jaryal AK, Jyotsna VP, Deepak KK (2013) Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing’s syndrome: role of endogenous hypercortisolism. Neuroendocrinology 97:309–317CrossRefPubMed

41.

Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK (2011) Effect of Cushing’s syndrome—endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci 160:99–102CrossRefPubMed

42.

Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533CrossRefPubMed

43.

Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, Pagnan A, Mantero F, Scaroni C (2006) Patients with Cushing’s syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 38:405–410CrossRefPubMed

44.

Fallo F, Famoso G, Capizzi D, Sonino N, Dassie F, Maffei P, Martini C, Paoletta A, Iliceto S, Tona F (2013) Coronary microvascular function in patients with Cushing’s syndrome. Endocrine 43:206–213CrossRefPubMed

45.

Rizzoni D, Porteri E, De Ciuceis C, Rodella LF, Paiardi S, Rizzardi N, Platto C, Boari GE, Pilu A, Tiberio GA, Giulini SM, Favero G, Rezzani R, Rosei CA, Bulgari G, Avanzi D, Rosei EA (2009) Hypertrophic remodeling of subcutaneous small resistance arteries in patients with Cushing’s syndrome. J Clin Endocrinol Metab 94:5010–5018CrossRefPubMed

46.

Barahona MJ, Resmini E, Viladés D, Pons-Lladó G, Leta R, Puig T, Webb SM (2013) Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 98:1093–1099CrossRefPubMed

47.

Bourdeau I, Bard C, Noël B, Leclerc I, Cordeau MP, Bélair M, Lesage J, Lafontaine L, Lacroix A (2002) Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87:1949–1954PubMed

48.

Starkman MN, Gebarski SS, Berent S, Schteingart DE (1992) Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 32:756–765CrossRefPubMed

49.

Dimopoulou C, Ising M, Pfister H, Schopohl J, Stalla GK, Sievers C (2013) Increased prevalence of anxiety-associated personality traits in patients with Cushing’s disease: a cross-sectional study. Neuroendocrinology 97:139–145CrossRefPubMed

50.

Langenecker SA, Weisenbach SL, Giordani B, Briceño EM, Guidotti Breting LM, Schallmo MP, Leon HM, Noll DC, Zubieta JK, Schteingart DE, Starkman MN (2012) Impact of chronic hypercortisolemia on affective processing. Neuropharmacology 62:217–225CrossRefPubMedCentralPubMed

51.

Toffanin T, Nifosì F, Follador H, Passamani A, Zonta F, Ferri G, Scanarini M, Amistà P, Pigato G, Scaroni C, Mantero F, Carollo C, Perini GI (2011) Volumetric MRI analysis of hippocampal subregions in Cushing’s disease: a model for glucocorticoid neural modulation. Eur Psychiatry 26:64–67CrossRefPubMed

52.

Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 46:1595–1602CrossRefPubMed

53.

Starkman MN, Giordani B, Gebarski SS, Schteingart DE (2007) Improvement in mood and ideation associated with increase in right caudate volume. J Affect Disord 101:139–147CrossRefPubMed

54.

Starkman MN, Giordani B, Gebarski SS, Schteingart DE (2003) Improvement in learning associated with increase in hippocampal formation volume. Biol Psychiatry 53:233–238CrossRefPubMed

55.

Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA, Starkman MN (2007) Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc 13:21–29CrossRefPubMed

56.

Resmini E, Santos A, Gómez-Anson B, Vives Y, Pires P, Crespo I, Portella MJ, de Juan-Delago M, Barahona MJ, Webb SM (2012) Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97:663–671CrossRefPubMed

57.

Resmini E, Santos A, Gómez-Anson B, López-Mourelo O, Pires P, Vives-Gilabert Y, Crespo I, Portella MJ, de Juan-Delago M, Webb SM (2013) Hippocampal dysfunction in cured Cushing’s syndrome patients, detected by (1) H-MR-spectroscopy. Clin Endocrinol 79:700–707

58.

Andela CD, van der Werff SJ, Pannekoek JN, van den Berg SM, Meijer OC, van Buchem MA, Rombouts SA, van der Mast RC, Romijn JA, Tiemensma J, Biermasz NR, van der Wee NJ, Pereira AM (2013) Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing’s disease: a case-control study. Eur J Endocrinol 169:811–819CrossRefPubMed

59.

Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA, Pereira AM (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95:E129–E141CrossRefPubMed

60.

Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM, Trainer PJ (1998) Menstrual abnormalities in women with Cushing’s disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83:3083–3088PubMed

61.

Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK (2006) Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91:447–453CrossRefPubMed

62.

Whirledge S, Cidlowski JA (2010) Glucocorticoids, stress, and fertility. Minerva Endocrinol 35:109–125PubMedCentralPubMed

63.

Shibli-Rahhal A, Van Beek M, Schlechte JA (2006) Cushing’s syndrome. Clin Dermatol 24:260–265CrossRefPubMed

64.

Davidovici BB, Orion E, Wolf R (2008) Cutaneous manifestations of pituitary gland diseases. Clin Dermatol 26:288–295CrossRefPubMed

65.

Minetto MA, Lanfranco F, Botter A, Motta G, Mengozzi G, Giordano R, Picu A, Ghigo E, Arvat E (2011) Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing’s disease. Eur J Endocrinol 164:985–993CrossRefPubMed

66.

Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II (2013) Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporos Int 24:2191–2199CrossRefPubMed

67.

Lekva T, Ueland T, Bøyum H, Evang JA, Godang K, Bollerslev J (2012) TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related tobone turnover. Eur J Endocrinol 166:1039–1048CrossRefPubMed

68.

Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing’s syndrome. J Bone Miner Res 24:1841–1846CrossRefPubMed

69.

Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865PubMed

70.

Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118CrossRefPubMed

71.

Randazzo ME, Grossrubatscher E, Ciaramella PD, Vanzulli A, Loli P (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15:193–201CrossRefPubMed

72.

Koch CA, Tsigos C, Patronas NJ, Papanicolaou DA (1999) Cushing’s disease presenting with avascular necrosis of the hip: an orthopedic emergency. J Clin Endocrinol Metab 84:3010–3012PubMed

73.

Giovansili I, Belange G, Affortit A (2013) Cushing disease revealed by bilateral atypical central serous chorioretinopathy: case report. Endocr Pract 19:e129–e133CrossRefPubMed

74.

Giugni AS, Mani S, Kannan S, Hatipoglu B (2013) Exophthalmos: a forgotten clinical sign of Cushing’s syndrome. Case Rep Endocrinol. doi:10.1155/2013/205208 PubMedCentralPubMed

75.

Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus AR (2012) Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur J Endocrinol 167:687–695CrossRefPubMed

76.

Alcalar N, Ozkan S, Kadioglu P, Celik O, Cagatay P, Kucukyuruk B, Gazioglu N (2013) Evaluation of depression, quality of life and body image in patients with Cushing’s disease. Pituitary 16:333–340CrossRefPubMed

77.

Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome. Eur J Endocrinol 165:527–535CrossRefPubMed

78.

Da Mota F, Murray C, Ezzat S (2011) Overt immune dysfunction after Cushing’s syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab 96:E1670–E1674CrossRefPubMed

79.

Russo L, Vitti P, Pinchera A, Marinò M (2010) Exacerbation of autoimmune thyroiditis following bilateral adrenalectomy for Cushing’s syndrome. Thyroid 20:669–670CrossRefPubMed

80.

Peixoto I, Maquine G, Francesconi VA, Francesconi F (2010) Dermatophytosis caused by Tricophyton rubrum as an opportunistic infection in patients with Cushing disease. An Bras Dermatol 85:888–890CrossRefPubMed

81.

Scheffel RS, Dora JM, Weinert LS, Aquino V, Maia AL, Canani LH, Goldani LZ (2010) Invasive fungal infections in endogenous Cushing’s syndrome. Infect Dis Rep 2:e4CrossRefPubMedCentralPubMed

82.

Kronfol Z, Starkman M, Schteingart DE, Singh V, Zhang Q, Hill E (1996) Immune regulation in Cushing’s syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones. Psychoneuroendocrinology 21:599–608CrossRefPubMed

83.

Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M, Lombardi G, Colao A (2003) Nephrolithiasis in Cushing’s disease: prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88:2076–2080CrossRefPubMed

84.

Storr HL, Alexandraki KI, Martin L, Isidori AM, Kaltsas GA, Monson JP, Besser GM, Matson M, Evanson J, Afshar F, Sabin I, Savage MO, Grossman AB (2011) Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing’s disease. Eur J Endocrinol 164:667–674CrossRefPubMed

85.

Dupuis CC, Storr HL, Perry LA, Ho JT, Ahmed L, Ong KK, Dunger DB, Monson JP, Grossman AB, Besser GM, Savage MO (2007) Abnormal puberty in paediatric Cushing’s disease: relationship with adrenal androgen, sex hormone binding globulin and gonadotrophin concentrations. Clin Endocrinol 66:838–843CrossRef

86.

Keil MF (2013) Quality of life and other outcomes in children treated for Cushing syndrome. J Clin Endocrinol Metab 98:2667–2678CrossRefPubMedCentralPubMed

Titel: Clinical and biochemical manifestations of Cushing’s
verfasst von: Georgia Ntali
Ashley Grossman
Niki Karavitaki
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2015
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-014-0631-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Silent corticotroph adenomas

Bilateral adrenalectomy for Cushing’s disease

A pitfall in diagnosing Cushing’s disease: ectopic ACTH-producing pituitary adenoma in the sphenoid sinus

Diagnosis of Cushing’s disease

Cushing disease: Where do we stand, where are we heading?